1. In Vivo

Biotech’s Next Goal: ‘Addressing Resistance’ In The ADC Space

Indispensable Value Of Partnerships Discussed by German Biopharma

 
• By Anabel Costa-Ferreira

George Badescu, chief business officer at Heidelberg Pharma, discusses antibody-drug conjugate development, partnership styles and the appetite for risk-taking in the biopharma industry.

Partnerships On The Rise • Source: Shutterstock

The cruciality of partnerships in business was stressed by George Badescu, chief business officer (CBO) at oncology therapies company Heidelberg Pharma AG, during a talk at the BIO-Europe Spring conference.

Badescu also profiled the company's lead asset and spoke of a growing appetite for risk-taking in the biopharma industry, while...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.